2025-02-19 - Analysis Report
## Intuitive Surgical Inc. (ISRG) Stock Analysis

**0. Summary Statistics:**

* **Ticker:** ISRG
* **Company:** Intuitive Surgical Inc. (a leading medical device company specializing in robotic-assisted surgery).
* **Cumulative Return (ISRG):** 331.64%
* **Cumulative Return (VOO):** 121.84%
* **Return Difference (ISRG - VOO):** 209.8%
* **Relative Return Difference:** 94.0% (indicating ISRG's performance is significantly higher than VOO historically, based on the provided range).


**1. Performance Comparison & Alpha/Beta Analysis:**

ISRG has significantly outperformed the S&P 500 (VOO) over the periods analyzed, with a cumulative return more than double that of VOO. The relative return difference suggests ISRG's outperformance is consistently high compared to its historical range.

The provided alpha/beta analysis shows high CAGR (Compound Annual Growth Rate) across most periods, suggesting strong historical growth.  Alphas are generally positive, particularly in recent years, implying outperformance relative to the market. Beta values fluctuate, indicating varying sensitivity to market movements. However, the high and consistently positive alpha in recent years (2021-2025) supports the strong relative performance.  The high CAGR coupled with relatively low MDD (Maximum Drawdown) during some periods suggests solid risk-adjusted returns.  It is important to note the potential biases of CAGR as a single metric and contextually assess MDD in conjunction with the growth rates.

**2. Recent Price Movement:**

* **Closing Price:** $595.55
* **5-Day Moving Average:** $592.78
* **20-Day Moving Average:** $587.84
* **60-Day Moving Average:** $556.35

The stock price is slightly above its 5-day and 20-day moving averages, indicating short-term upward momentum.  However, it's notably higher than its 60-day moving average, suggesting stronger medium-term upward momentum.

**3. Technical Indicators & Expected Return:**

* **RSI:** 65.87 (Slightly above the neutral 50, indicating somewhat overbought conditions, but not excessively so.)
* **PPO:** -0.11 (Negative, indicating bearish momentum, counterintuitively given other metrics.)
* **Relative Divergence (20-day):** +2.5 (Short-term upward trend).
* **Expected Return (2+ years):** 19.7% (Significant outperformance relative to the S&P 500, however, this is just an expectation and not guaranteed.)


The discrepancy between the positive short-term trend indicated by the moving averages and relative divergence, and the negative PPO, warrants further investigation.  This could point to a potential near-term correction or consolidation phase, despite long-term strength.


**4. Recent Earnings Analysis:**

| Date       | EPS    | Revenue      |
|------------|--------|-------------|
| 2024-10-18 | $1.59  | $2.04 B      |
| 2024-07-19 | $1.48  | $2.01 B      |
| 2024-04-19 | $1.54  | $1.89 B      |
| 2023-10-20 | $1.18  | $1.74 B      |
| 2024-10-18 | $1.18  | $1.74 B      | *(There appears to be a duplicate entry here.  This data needs clarification.)*


Revenue shows a generally upward trend, but EPS fluctuates slightly.  Further analysis with a corrected dataset and additional financial information is required for more robust conclusions.  The apparent duplication in the last row needs to be addressed.

**5. Financial Information:**

The absence of "Total Revenue" and "Gross Profit" data severely limits a comprehensive financial analysis.  This data is crucial for assessing profitability, margins, and overall financial health.  Without this data, a reliable assessment of financial health and risk is not possible.


**6. Overall Analysis:**

ISRG has demonstrated exceptional historical performance significantly exceeding the S&P 500.  The high CAGR and generally positive alpha scores suggest strong potential for continued outperformance.  However, current technical indicators present a mixed picture, with some suggesting short-term upward momentum and others indicating bearish sentiment. The lack of crucial financial data (Total Revenue, Gross Profit) hinders a complete financial health evaluation.  Therefore, while historical performance is very positive,  a complete and balanced investment decision requires more comprehensive data and a deeper understanding of the company's current financial situation and future prospects.  The expected return of 19.7% should be viewed with caution and should not be interpreted as a guarantee.  Thorough due diligence is recommended before any investment decision.
